David Veitch, the chief commercial officer at Basilea Pharmaceutica Ltd, has been chosen to succeed Ronald Scott as chief executive following Mr Scott’s retirement in April. Mr Veitch joined Basilea in 2014 and as chief commercial officer, led the launch of two hospital anti-infective products. In addition, he executed partnerships with pharma companies around the world. Prior to joining Basilea, he was president of European operations at Savient Pharmaceuticals Inc and before that, an executive at Bristol-Myers Squibb Co. Mr Veitch holds a BSc in biology from the University of Bristol, UK.
Basilea announced appointment on 21 February 2018.
Copyright 2018 Evernow Publishing Ltd